Safety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer
A phase 1/2 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by Smartwise Sweden AB, now recruiting.
Overview
Safety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer is a phase 1/2 interventional study registered as NCT07575191 by Smartwise Sweden AB, with 9 participants planned, started 2026-04-29 and due to reach its primary completion in 2027-12. Interventions recorded: Gemcitabine and Extroducer Infusion Catheter System.
Similar pages
not linked directly; found by shared links- TrialStudy of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialIntra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialEvaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialClinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialPolymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialA Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialIN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.